← The library
Thymosin Alpha-1 (Thymalfasin)
Immune/Anti-infEvidence grade
BRegion-specific approval (not US FDA)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions
Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.
PurposeImmune modulation
MechanismImmune signaling peptide used in some countries for certain conditions
EffectsImmune signaling peptide used in some countries for certain conditions
DosingNo human dose established.
Bottom lineUsed clinically in some countries; not standard in the US—specialist oversight.
Protocols · as published2 sourced
Label — Zadaxin (approved outside the US; not FDA)Zadaxin (chronic hepatitis B)
RouteSubcutaneous; not for IV use
FrequencyTwice weekly, about 3-4 days apart
Starting1.6 mg (900 mcg/m2) SC twice a week
EscalationNone
Target1.6 mg SC twice a week for 6 to 12 months. Under 40 kg: 40 mcg/kg.
From RxList, a secondary reproduction of the label; the original SciClone PI was not fetched.
SourceRxList — Zadaxin ↗
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous (abdomen, thigh or upper arm, rotated)
FrequencyTwice weekly
Starting1.6 mg SC twice weekly (same as the label)
EscalationNone
Target1.6 mg twice weekly
Cycle6 months (hep B), up to 12 months; 4-12 weeks for "general immune support" (community, no label or trial basis)
WhereAbdomen, thigh or upper arm, with rotation.
Batches on filenone
No tested batches on file.
Cautions & interactions
Regulatory status varies; medical supervision required
No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.
CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.